Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Timothy Bray

Orthopaedic Trauma Reno, NV Medical Doctor

NPI 1639150568 CMS profile 119216

555 N Arlington Ave, Reno, NV 89503

Open in the dashboard

General payments

$11,239

53 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$132,750

4 holdings reported · through program year 2024

Through program year 2024, Timothy Bray of Reno, NV is reported in the CMS Open Payments database as having received $11,239 across 53 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $132,750 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $354 5
2022 General $157 7
2021 General $362 5
2020 General $258 3
2019 General $10,090 32
2022 Ownership $35,000 1
2021 Ownership $34,000 1
2020 Ownership $32,500 1
2019 Ownership $31,250 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Bray
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Timothy Bray were reported at $0. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Timothy Bray Orthopaedic Trauma median Middle half National median
2019 $10,090 $1,475 $264–$6,401 $163
2020 $258 $596 $120–$4,020 $114
2021 $362 $919 $171–$4,697 $132
2022 $157 $1,547 $272–$7,240 $149
2023 $354 $1,330 $247–$5,875 $160
2024 $19 $1,288 $277–$6,797 $164
2025 $0 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Acell, Inc. $10,080 33 payments
  2. Stryker Corporation $406 5 payments
  3. Smith+Nephew, Inc. $232 2 payments
  4. Flexion Therapeutics, Inc. $138 1 payment
  5. Acumed LLC $125 1 payment
  6. Conformis, Inc. $77 3 payments
  7. Kerecis Limited $48 1 payment
  8. Integra LifeSciences Corporation $24 1 payment
  9. Next Science LLC $24 1 payment
  10. SI-BONE, Inc. $22 1 payment
  11. Other $64 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Education $7,890 13 payments
  2. Food and Beverage $1,834 31 payments
  3. Travel and Lodging $1,515 9 payments
Products named General payments · program years 2019–2024
  1. T2 $228 3 payments
  2. T2 ALPHA $159 1 payment
  3. Zilretta $138 1 payment
  4. CORI $130 1 payment
  5. Anatomic Radial Head System $125 1 payment
  6. RibLoc $125 1 payment
  7. BioBridge $125 1 payment
  8. Clavicle Plating System $125 1 payment
  9. Polarus 3 Solution $125 1 payment
  10. EVOS $102 1 payment
  11. Other $946 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

331

Median for Orthopedic Surgery: 203

Drug cost

$2,841

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 106 $1,899
Methylprednisolone Generic 108 $676
Meloxicam Generic 51 $153
Tramadol Hcl Generic 40 $73
Amoxicillin Generic 26 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$45,411

Of which drugs: $11,657

Medicare patients

308

Average age 74

Services billed

1,269

201 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 68%
High blood pressure 65%
Osteoporosis 22%
Diabetes 21%
Chronic kidney disease 20%
Ischemic heart disease 19%
Depression 18%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 35 162 $751

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record